FDA
-
-
-
-
-
-
-
Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis
-
-
-
-
-
-
-
Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis
-
-
-
-
-
-
-
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
-
-
-
-
-
-
-
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
-
-
-
-
-
-
-
Navidea Biopharma (NAVB) Provides Statement Regarding COVID-19 Pandemic
-
-
-
-
-
-
-
Navidea Biopharmaceuticals Announces Day and Time of SNMMI Presentation of Phase 1/2 Study Results and Enrollment Update on its Phase 2B Study
-
-
-
-
-
-
-
Navidea Biopharma (NAVB) Reports Patent Extension for Lymphoseek
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

